You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A simple assay system for rapid detection of circulating tumor cells
SBC: TELOVISION, LLC Topic: NCIDESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery
SBC: DISCOVERYBIOMED, INC. Topic: NIDCDPrincipal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Chronic intrapulmonary delivery of a novel small molecule Wnt/beta-catenin inhibitor for Idiopathic Pulmonary Fibrosis
SBC: BETA CAT PHARMACEUTICALS, INC. Topic: NHLBIProject Summary Idiopathic pulmonary fibrosisIPFis a devastatingprogressive disease with no known cure and no treatment that convincingly alters the disease course or significantly improves mortalityThe objective of this proposal is the development of nebulized delivery of the small molecule inhibitor of Wntcatenin signalingBCfor Idiopathic Pulmonary FibrosisPre clinical studies in rodentsdogsand ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of a Rapid Blood Test for Traumatic Brain Injury
SBC: Fawkes Biotechnology, LLC Topic: 100Traumatic brain injuryTBIis a substantial health care issue affecting both civilian and military populationsAlthough extremes of head injury are recognizablemild to moderate TBImmTBIis more difficult to diagnose leading to a need for the identification of circulating biomarkers of brain injury that may facilitate early identificationUsing a rat model of TBI we identified a novel marker of neuronal ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of fully integrated electrochemical device for detecting metals in biological fluids
SBC: Bioanalytical Systems, Inc. Topic: NIEHSExposure to toxic levels of metals causes significant negative chronic health problems in the exposed populationsDuring and after exposuremetals such as manganeseleadnickelmercuryetcare present in biological fluidsA fully integrated wearable device would enable real time monitoring of exposure levelsThis would quickly alert those exposed to toxic concentrations of metals and mitigate the chronic h ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage
SBC: EXSCIEN CORPORATION Topic: NINDSDESCRIPTION (provided by applicant): Attempts to develop drug treatments for acute stroke have not fulfilled expectations. Perhaps best illustrating this unsatisfactory situation is the hisory of therapeutic strategies directed at the inhibition of reactive oxygen species (ROS). While decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire s ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Evaluating Synthetic Biology Produced Triterpene Oils in Adjuvant Formulations
SBC: Enepret Incorporated Topic: NIAIDABSTRACT Vaccine adjuvants help stimulate the body to generate an immune response when co injected with an antigenthe compound for which immunity is desiredAlthough the human body is capable of producing antibodies to most injected antigensadjuvants can help boost the body s ability to mount a successful and acquired immune response to the presented targetAdjuvants have been shown to enhance immun ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Exosomal drug formulations
SBC: 3P BIOTECHNOLOGIES, INC. Topic: NCIDESCRIPTION (provided by applicant): More people in the U.S. (160,340 per year) die of lung cancer than of prostate, breast, and colon cancer combined. The most common type of lung cancer, non-small-cell lung cancer (NSCLC), accounts for 75% of all lung cancers. Regrettably, 85% of all patients diagnosed with NSCLC eventually die of the disease within 5 years, due to micro-metastasis and relapse. ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Harvesting specific plant metabolites from hairy root cultures using magnetized n
SBC: NAPROGENIX, INC. Topic: NCCIHDESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point ofCare Applications
SBC: GENECAPTURE, INC. Topic: CBD15C001GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we p ...
STTR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense